Story perspectives

US Sends Experimental Ebola Antibody to Congo for Trials

6/24/2026

Summary

Story summary

The United States is sending experimental Ebola antibody MBP134 to the Democratic Republic of Congo for trials.
U.S. Health Department announced compassionate-use provision as World Health Organization (WHO) ships doses and coordinates enrollment with partners.
Trials of MBP134 and two Gilead antivirals will start in coming weeks under an Oxford-led study.
WHO Director-General Tedros Ghebreyesus said Phase 1 vaccine trials could start in July in the United Kingdom or Uganda.

1 of 1

Story summary

The United States is sending experimental Ebola antibody MBP134 to the Democratic Republic of Congo for trials.
U.S. Health Department announced compassionate-use provision as World Health Organization (WHO) ships doses and coordinates enrollment with partners.
Trials of MBP134 and two Gilead antivirals will start in coming weeks under an Oxford-led study.
WHO Director-General Tedros Ghebreyesus said Phase 1 vaccine trials could start in July in the United Kingdom or Uganda.